Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease

Journal of Clinical Investigation

Volumn 102, Issue 10, 1998, Pages 1882-1891

  Cooke, Kenneth R ^a,c   Hill, Geoffrey R ^a   Crawford, James M ^b   Bungard, David ^a   Brinson, Yani S ^a   Delmonte Jr , John ^a   Ferrara, James L M ^a,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bone marrow transplantation; Cytokines; Gastrointestinal damage; Murine; T cells

Indexed keywords

GAMMA INTERFERON; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; T LYMPHOCYTE ACTIVATION;

EID: 0032533897     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI4285     Document Type: Article

References (77)

1. Ferrara, J.L.M., and H.J. Deeg. 1991. Graft versus host disease. N. Engl. J. Med. 324:667-674.
2. Sherry, B., and A. Cerami. 1988. Cachectin/tumor necrosis factor exerts endocrine, paracrine and autocrine control of inflammatory responses. J. Cell Biol. 107:1269-1277.
3. D'Andrea, A., M. Rengaraju, N.M. Valiante, J. Chehimi, M. Kubin, M. Aste, S.H. Chan, M. Kobayashi, D. Young, E. Nickborg, et al. 1992. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med. 176:1387-1398.
4. Nestel F.P., K.S. Price, T.A. Seemayer, and W.S. Lapp. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 175:405-413.
5. McDonald, G.C., and J.G. Gartner. 1992. Prevention of acute lethal graft-versus-host disease in F1 hybrid mice by pretreatment of the graft with anti-NK-1.1 and complement. Transplantation. 54:147-151.
6. Braun, Y.M., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657-661.
7. Baker, M.B., N.H. Altman, E.R. Podack, and R.B. Levy. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183:2645-2656.
8. Hill, G.R., W. Krenger, and J.L.M. Ferrara. 1997. The role of cytokines in acute graft-versus-host disease. Cytokines Cell. Mol. Ther. 3:257-265.
9. Hill, G.R., J.M. Crawford, K.R. Cooke, Y.S. Brinson, L. Pan, and J.L.M. Ferrara. 1997. Total body irradiation effects on acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood. 90: 3204-3213.
10. Glode, L.M., and D.L. Rosenstreich. 1976. Genetic control of B cell activation by bacterial lipopolysaccharide is mediated by multiple distinct genes or alleles. J. Immunol. 117:2061-2066.
11. Watson, J., K. Kelly, M. Largen, and B.A. Taylor. 1978. The genetic mapping of a defective LPS response gene in C3H/Hej mice. J. Immunol. 120: 422-424.
12. Sultzer, B.M., R. Castagna, J. Bandekar, and P. Wong. 1993. Lipopolysaccharide nonresponder cells: the C3H/Hej defect. Immunobiology. 187:257-271.
13. Thieblemont, N., and S.D. Wright. 1997. Mice genetically hyporesponsive to lipopolysaccharide (LPS) exhibit a defect in endocytic uptake of LPS and ceramide. J. Exp. Med. 185:2095-2100.
14. Morrison, D.C., and J.L. Ryan. 1979. Bacterial endotoxins and host immune response. Adv. Immunol. 28:294.
15. Tough, D.F., S. Sun, and J. Sprent. 1997. T cell stimulation in vivo by lipopolysaccharide (LPS). J. Exp. Med. 185:2089-2094.
16. Sultzer, B.M., and G.W. Goodman. 1976. Endotoxin protein: a B cell mitogen and polyclonal activator of C3H/Hej lymphocytes. J. Exp. Med. 144: 821.
17. Sultzer, B.M. 1983. Lymphocyte activation by endotoxin and endotoxin protein: the role of the C3H/Hej mouse. In Beneficial Effects of Endotoxin. A. Nowotny, editor. Plenum Press, New York. 227.
18. + donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol. 155:585-593.
19. Down, J.D., P. Mauch, M. Warhol, S. Neben, and J.L.M. Ferrara. 1992. The effect of donor T lymphocytes and total-body irradiation on hematopoietic engraftment and pulmonary toxicity following experimental allogeneic bone marrow transplantation. Transplantation. 54:802-808.
20. Cooke, K.R., L. Kobzik, T.R. Martin, J. Brewer, J. Delmonte, J.M. Crawford, and J.L.M. Ferrara. 1996. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 88:3230-3239.
21. Blazar, B.R., P.A. Taylor, D.C. Snover, S.N. Sehgal, and D.A. Vallera. 1993. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J. Immunol. 151:5726-5741.
22. Blazar, B.R., P.A. Taylor, A. Panoskaltsis-Mortari, G.S. Gray, and D.A. Vallera. 1995. Co-blockade of the LFA1:ICAM and CD28/B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully MHC disparate donor grafts. Blood. 83:3815-3825.
23. Fontaine, P., and C. Perreault. 1990. Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers. Transplantation. 49:1177-1179.
24. Crawford, J.M. 1997. Graft-versus-host disease of the liver. In Graft-Versus-Host Disease, 2nd ed. J.L.M. Ferrara, H.J. Deeg, and S.J. Burakoff, editors. Marcel Dekker, Inc., New York. 315-336.
25. Mowat, A. 1997. Intestinal graft-versus-host disease. In Graft-Versus-Host Disease, 2nd ed. J.L.M. Ferrara, H.J. Deeg, and S.J. Burakoff, editors. Marcel Dekker, Inc., New York. 337-384.
26. Snover, D.C., S.A. Weisdorf, N.K. Ramsay, P. McGlave, and J.H. Kersey. 1984. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology. 4:123-130.
27. Snover, D.C., S.A. Weisdorf, G.M. Vercellotti, B. Rank, S. Hutton, and P.A. McGlave. 1985. Histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum. Pathol. 16:387-392.
28. Krenger, W., K.R. Cooke, S.T. Sonis, J. Crawford, R. Simmons, L. Pan, L. Kobzik, J. Delmonte, M. Karandikar, and J.L.M. Ferrara. 1996. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation. 62:1278-1285.
29. Mohler, K.M, D.S. Torrance, C.A. Smith, R.G. Goodwin, K.E. Stremler, V.P. Fung, H. Madani, and M.B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548-1561.
30. Galanos, C., and M.A. Freudenberg. 1993. Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology. 187:346-356.
31. Piguet, P.F., G.E. Grau, B. Allet, and P. Vassalli. 1987. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166:1280-1289.
32. Holler, E., H.H. Kolb, A. Moller, J. Kempeni, S. Lisenfeld, H. Pechumer, W. Lehmacher, G. Ruckdeschel, B. Gleixner, C. Riedner, et al. 1990. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 75:1011-1116.
33. Remberger M., O. Ringden, and L. Markling. 1994. TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant. 15:99-104.
34. Vella, A.T., T. Mitchell, B. Groth, P.S. Linsley, J.M. Green, C.B. Thompson, J.W. Kappler, and P. Marrack. 1997. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long term survival in vivo. J. Immunol. 158:4714-4720.
35. + T cells. J. Immunol. 159:591-598.
36. Gartner, J.G., A.C. Merry, and C.I. Smith. 1988. An analysis of pulmonary natural killer cell activity in F1-hybrid mice with acute graft-versus-host reactions. Transplantation. 46:879-886.
37. Hattori, K., T. Hirano, M. Tateno, K. Oshimi, N. Kayagaki, H. Yagita, and K. Okumura. 1997. The synergistic effects of anti-Fas ligand and TNF-α antibody on the prevention of lethal acute graft-versus-host disease in mice. Blood. 90:206a. (Abstr.)
38. Jacobs, C.A., M.P. Beckmann, K. Mohler, C.R. Maliszewski, W.C. Fanslow, and D.H. Lynch. 1992. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int. Rev. Exp. Pathol. 348:123-135.
39. Billingham, R.E. 1966. The biology of graft-versus-host reactions. Harvey Lect. 62:21.
40. Klingemann, H.G., R. Storb, A. Fefer, H.J. Deeg, F.R. Appelbaum, C.D. Buckner, M.A. Cheever, P.D. Greenberg, P.S. Stewart, K.M. Sullivan, et al. 1986. Bone marrow transplantation in patients aged 45 years and older. Blood. 67:770-776.
41. Weisdorf, D., R. Hakke, B. Blazar, W. Miller, P. McGlave, N. Ramsay, J. Kersey, and A. Filipovitch. 1991. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 51:1197-1203.
42. Johnsen, H.E., L. Bostrom, J. Moller, J.A. Jorgensen, L. Jensen, and O. Ringden. 1992. A study of donor alloreactivity, which may predict acute graft-versus-host disease in HLA identical bone marrow transplantation for early leukemia. Scand. J. Immunol. 35:353-360.
43. Theobald, M., T. Nierle, D. Bunjes, R. Arnold, and H. Heimpel. 1992. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N. Eng. J. Med. 327:1613-1617.
44. Sviland, L., A.M. Dickinson, P.J. Carey, A.D.J. Pearson, and S.J. Proctor. 1990. An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 5:105-109.
45. van Els, C.A., A. Bakker, A.H. Zwinderman, F.E. Zwaan, J.J. van Rood, and E. Goulmy. 1990. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. Transplantation. 50:67-71.
46. Niederwieser, D., A. Grassegger, J. Aubock, M. Herold, C. Nachbaur, A. Rosenmayr, A. Gachter, W. Nussbaumer, S. Gaggl, and C. Huber. 1993. Correlation of minor histocompatibility antigens-specific cytotoxic T lymphocytes with graft-versus-host disease status and analysis of tissue distribution of their target antigens. Blood. 81:2200-2208.
47. Chao, N.J. 1994. Clinical aspects of graft-versus-host disease. In Medical Intelligence Unit: Graft-Versus-Host Disease. R.G. Landes Company, Austin, TX. 68-84.
48. van Els, C.A., A. Bakker, A.H. Zwinderman, F.E. Zwaan, J.J. van Rood, and E. Goulmy. 1990. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation. 50:62-66.
49. Theobald, M., D. Bunjes, T. Nierle, R. Arnold, and H. Heimpel. 1993. Measurement of recipient-specific alloreactivity: is GVHD predictable? Bone Marrow Transplant. 12(Suppl.):S18-23.
50. Kaminski, E., J. Hows, S. Man, P. Brookes, S. Mackinnon, T. Hughes, O. Avakian, J.M. Goldman, and J.R. Batchelor. 1989. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation. 48:608-613.
51. Xun, C.Q., J.S. Thompson, C.D. Jennings, S.A. Brown, and M.B. Widmer. 1994. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2 incompatible transplanted SCID mice. Blood. 83:2360-2367.
52. Antin, J., and J.L.M. Ferrara. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood. 80:2964-2968.
53. Schwaighofer, H., N.A. Kernan, R.J. O'Reilly, J. Brankova, D. Nachbaur, M. Herold, B. Eibl, and D. Niederwieser. 1996. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation. Transplantation. 62:947-953.
54. Holler, E., H.J. Kolb, J. Mittermuller, M. Kaul, G. Ledderose, Th. Duell, B. Seeber, M. Schleuning, R. Hintermeier-knabe, B. Ertl, et al. 1995. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood. 86:890-899.
55. Holler, E., B. Ertl, R. Hintermeier-Knabe, M.G. Roncarolo, G. Eissner, F. Mayer, P. Fraunberger, U. Behrends, W. Pfannes, H.J. Kolb, et al. 1997. Inflammatory reactions induced by pretransplant conditioning - an alternative target for modulation of acute GVHD and complications following allogeneic bone marrow transplantation? Leuk. Lymphoma. 25:217-224.
56. Carroll, M.C., P. Katzman, E.M. Alicot, B.H. Koller, D.E. Geraghty, H.T. Orr, and J.L. Strominger. 1987. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc. Natl. Acad. Sci. USA. 84:8535-8539.
57. Jacob, C.O., Z. Fronek, G.D. Lewis, M. Koo, J.A. Hansen, and H.O. McDevitt. 1990. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA. 87:1233-1237.
58. Abraham, L.J., M.A. French, and R.L Dawkins. 1993. Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor alpha. Clin. Exp. Immunol. 92:14-18.
59. Mayer, F.R., G. Messer, W. Knabe, W. Mempel, M. Meurer, H.J. Kolb, and E. Holler. 1996. High response of TNFα secretion in vivo in patients undergoing BMT may be associated with the -308 bp TNF-α-gene enhancer-polymorphism. Bone Marrow Transplant. 17:s101. (Abstr.)
60. Price, K.S., F.P. Nestel, and W.S. Lapp. 1997. Progressive accumulation of bacterial lipopolysaccharide in vivo during murine acute graft-versus-host disease. Scand. J. Immunol. 45:294-300.
61. Seemayer, T.A., F.P. Nestel, K. Kichian, K.E. You-Ten, J. Desbarats, K. Price, P. Ponka, and W.S. Lapp. The role of endotoxin in the pathogenesis of acute graft-versus-host disease. In Graft-Versus-Host Disease, 2nd ed. J.L.M. Ferrara, H.J. Deeg, and S.J. Burakoff, editors. Marcel Dekker, Inc., New York. 502-523.
62. Eissner, G., F. Kohlhuber, M. Grell, M. Ueffing, P. Scheurich, A. Hieke, G. Multhoff, G.W. Bornkamm, and E. Holler. 1995. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood. 86:4184-4193.
63. Remick, D.G. Lung and gut injury induced by tumor necrosis factor. 1993. Res. Immunol. 144:326-331.
64. Ghayur, T., T. Seemayer, and W.S. Lapp. 1990. Histologic correlates of immune functional deficits in graft-vs.-host disease. In Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. S.J. Burakoff, H.J. Deeg, J. Ferrara, and K. Atkinson, editors. New York: Marcel Dekker, Inc. 109-132.
65. Lin, T., T. Brunner, B. Tietz, J. Madsen, E. Bonfoco, M. Reaves, M. Huflejt, and D.R. Green. 1998. Fas ligand-mediated killing by intestinal intraepithelial lymphocytes - participation in intestinal graft-versus-host disease. J. Clin. Invest. 101:570-577.
66. Fowler, D.H., K. Kurasawa, A. Husebekk, P.A. Cohen, and R.E. Gress. 1994. Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J. Immunol. 152:1004-1013.
67. Trepicchio, W.L., L. Wang, M. Bozza, and A.J. Dorner. 1997. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-κB. J. Immunol. 159:5661-5670.
68. Hill, G.R., K.R. Cooke, J.M. Crawford, J.C. Keith, Jr., Y.S. Brinson, D. Bungard, and J.L.M. Ferrara. 1998. Interleukin-11 promotes Th2 polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102:115-123.
69. van Bekkum, D.W., J. Roodenburg, P.J. Heidt, and D. van der Waaij. 1974. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J. Natl. Cancer Inst. 52:401-404.
70. van Bekkum, D.W., and S. Knaan. 1977. Role of bacterial microflora in development of intestinal lesions from graft versus host disease. J. Natl. Cancer Inst. 58:787-790.
71. Moller, J., P. Skirhoj, N. Hoiby, and F.B. Peterson. 1982. Protection against graft versus host disease by gut sterilization? Exp. Hematol. 10:101-103.
72. Storb, R., R.L. Prentice, C.D. Buckner, R.A. Clift, F. Appelbaum, J. Deeg, K. Doney, J.A. Hansen, M. Mason, J.E. Sanders, et al. 1983. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N. Engl. J. Med. 308:302-307.
73. Jackson, S.K., J. Parton, R.A. Barnes, C.H. Poynton, and C. Fegan. 1993. Effect of IgM-enriched intravenous immunoglobulin (pentaglobulin) on endotoxemia and anti-endotoxin antibodies in bone marrow transplantation. Eur. J. Clin. Invest. 23:540-545.
74. Haziot, A., G.W. Rong, X.Y. Lin, J. Silver, and S.M. Goyert. 1995. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J. Immunol. 154:6529-6532.
75. Christ, W.J., O. Asano, A.L.C. Robidoux, M. Perez, Y. Wang, G.R. Dubuc, W.E. Gavin, L.D. Hawkins, P.D. McGuinness, M.A. Mullarkey, et al. 1995. E5531, a pure endotoxin antagonist of high potency. Science. 268:80-83.
76. Leturcq, D.J., A.M. Moriarty, G. Talbott, R.K. Winn, T.R. Martin, R.J. Ulevitch. 1996. Antibodies against CD14 protect primates from endotoxin-induced shock. J. Clin. Invest. 98:1533-1538.
77. Lamping, N., R. Dettmer, N.W.J. Schroder, D. Pfeil, W. Hallatschek, R. Burger and R.R. Schumann. 1998. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J. Clin. Invest. 101:2065-2071.